PIRAMAL ENTERPRISES LTD. - 500302 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Proceedings and Voting Results of the 75th Annual General Meeting of the Piramal Enterprises Limited29-07-2022
29-07-2022
PIRAMAL ENTERPRISES LTD. - 500302 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings and Voting Results of the 75th Annual General Meeting ('AGM') of the Piramal Enterprises Limited ('the Company')29-07-2022
PIRAMAL ENTERPRISES LTD. - 500302 - Report Of The Auditors On Financial Results For The Quarter Ended 30Th June, 2022
In continuation to our financial results for the quarter ended 30th June, 2022 filed with the stock exchanges after the Board Meeting held today, please find attached independent auditor's reports on these financial results with Unique Document Identification Number. This is also available on the Company''s website at www.piramal.com29-07-2022
Piramal Enterprises Q1 net profit slips 9% to Rs 486 cr; revenue up 22%
Piramal Enterprises Ltd on Friday reported an 8.95 per cent decline in consolidated net profit to Rs 485.98 crore for the first quarter ended June 30, impacted by higher expenses. The company had posted a consolidated net profit of Rs 533.79 crore in the same period last fiscal, Piramal Enterprises Ltd (PEL) said in a regulatory filing. Its revenue from operations in the first quarter stood at Rs 3,548.37 crore compared to Rs 2,908.68 crore in the year-ago period, it added. Total expenses in the quarter were higher at Rs 3,252.09 crore against Rs 2,492.97 crore a year ago. PEL said its pharmaceuticals vertical clocked revenue of Rs 1,485.43 crore, up from Rs 1,362.02 crore in the year-ago quarter. The financial services segment registered a revenue of Rs 2,062.94 crore against Rs 1,546.66 crore in the first quarter of the last fiscal, the company added. "In financial services, we achieved significant growth in retail disbursements through our branches as well as by leveraging dig29-07-2022
PIRAMAL ENTERPRISES LTD. - 500302 - Announcement Under Regulation 30 (LODR)-Resignation Of Director
Intimation of Resignation of Mr. Khushru Jijina as Executive Director of the Company29-07-2022
PIRAMAL ENTERPRISES LTD. - 500302 - Intimation Of Change In The Chief Financial Officer (KMP) Of The Company
Intimation of Change in the Chief Financial Officer (KMP) of the Company29-07-2022
Q1FY23 Quarterly Result Announced for Piramal Enterprises Ltd.
Finance firm Piramal Enterprises Announced Q1FY23 Result : On-track to complete the Pharma demerger and simplification of the corporate structure by Q3 FY23, subject to various approvals PEL received the license from the Reserve Bank of India (RBI) to commence business as a non-banking finance institution (NBFC) Q1 FY23 Revenues grew 22% YoY to INR 3,548 Cr.; Q1 FY23 PAT at INR 486 Cr. Overall AUM grew +37 % YoY to INR 64,590 Cr.; retail loan book grew 332% YoY to INR 22,267 Cr. Pharma business revenues grew 9% YoY to INR 1,485 Cr for Q1 FY23 India Consumer Healthcare grew 17% YoY and Complex Hospital Generics business grew 10% YoY during the quarter Strengthened Piramal Pharma Board by inducting three new board members Overall Performance: Q1 FY23 revenue growth of 22 % YoY to INR 3,548 Cr. Vs INR 2,909 Cr. in Q1 FY22 Net Profit at INR 486 Cr. Vs. INR 534 Cr. in Q1 FY22 Financial Services (FS lending): Overall AUM grew +37 % YoY to INR 64,590 Cr. Retail loan book grew 4x YoY to INR 22,267 Cr. Retail loan disbursements increased 66% QoQ and ~13x YoY in Q1 FY23 to INR 2,459 Cr. FS business Pre-provision Operating Profit of INR 621 Cr. in Q1 FY23 vs. INR 378 Cr. in Q1 FY22 Cost of borrowings declined 130bps YoY and 40bps QoQ to 8.8% Launched Microfinance business in May-2022 Focus on talent, technology and governance structure for wholesale 2.0 on track Pharma Business: Pharma business revenues grew 9% YoY to INR 1,485 Cr for Q1 FY23 India Consumer Healthcare grew 17% YoY and Complex Hospital Generics business grew 10% YoY Planned capacity expansion in niche capabilities for the CDMO business at Aurora (Canada), Pithampur (India) and Digwal (India) completed Appointment of Mr. Herve Berdou as Chief Operating Officer, CDMO Strong growth in inhaled anaesthesia sales in the US. Intrathecal portfolio continues to command market share in the US Launched 7 new products in the India Consumer Healthcare business in Q1 FY23. Power brands showing strong growth. Ajay Piramal, Chairman, Piramal Enterprises Ltd. said, “We had a steady first quarter delivering revenues of INR 3,548 Cr. and net profits of INR 486 Cr. In financial services, we achieved significant growth in retail disbursements through our branches as well as by leveraging digital lending capabilities. We remain ahead on our target to achieve disbursement levels of INR 2,500-3,500 Cr. by the third quarter of this financial year. This is in line with our endeavor to better serve the customers in the tier 2 and tier 3 cities of Bharat. In wholesale, we continue to focus on making our existing loan book more granular as well as building a healthy deal pipeline across real estate and corporate lending, as part of the ‘Wholesale Lending 2.0’ strategy. We expect to double our loan book in the next 5 years, thereby achieving significant growth and making our overall loan book more retailoriented. In pharmaceuticals, we have been making both organic and inorganic investments across all our businesses. We have also demonstrated consistent execution against key strategic priorities. Our global footprint with a diversified revenue base, presence in attractive segments with high entry barriers, capability to meet a wide range of customer requirements across multiple geographies and best-in-class quality track record, provides greater stability from a long- term investment perspective. We remain firmly on track to complete the demerger of the pharmaceuticals business by Q3 FY23 and unlock significant value for our stakeholders." Result PDF29-07-2022
PIRAMAL ENTERPRISES LTD. - 500302 - Board Meeting Outcome for Outcome Of Board Meeting- Unaudited Financial Results (Standalone & Consolidated) For The Quarter Ended 30Th June, 2022
In compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), the Board of Directors of the Company at its meeting held today, i.e. 29th July, 2022, has inter alia, approved the Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter ended 30th June, 2022. In this regard, please find enclosed the following: 1. Unaudited Financial Results (Standalone & Consolidated) for the quarter ended 30th June, 2022 along with information under Regulation 52(4) of the Listing Regulations; 2. Limited Review Report by the Auditors; 3. Statement of deviation(s) or variation(s) for the quarter ended 30th June, 2022 under Regulation 52(7) of the Listing Regulations; and 4. Press Release and Presentation to the investors.29-07-2022
PIRAMAL ENTERPRISES LTD. - 500302 - Unaudited Financial Results (Standalone & Consolidated) For The Quarter Ended 30Th June, 2022
In compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company at its meeting held today, i.e. 29th July, 2022, has inter alia, approved the Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter ended 30th June, 2022. In this regard, please find enclosed the following: 1. Unaudited Financial Results (Standalone & Consolidated) for the quarter ended 30th June, 2022 along with information under Regulation 52(4) of the Listing Regulations; 2. Limited Review Report by the Auditors; 3. Statement of deviation(s) or variation(s) for the quarter ended 30th June, 2022 under Regulation 52(7) of the Listing Regulations; and 4. Press Release and Presentation to the investors.29-07-2022
PIRAMAL ENTERPRISES LTD. - 500302 - Announcement under Regulation 30 (LODR)-Meeting Updates
Regulations 29 & 50 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 201528-07-2022